We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biochip Detects MI by Analyzing Saliva

By HospiMedica staff writers
Posted on 28 Apr 2008
Early diagnosis of a myocardial infarction (MI) may now be possible using only a few drops of saliva and a new nano-biochip, according to a new report.

Researchers at the University of Texas (UT, Austin, USA), in collaboration with scientists and clinicians at the University of Kentucky (Lexington, USA), the University of Louisville (KY, USA), and The University of Texas Health Science Center (San Antonio, TX, USA), took advantage of the recent identification of a number of blood serum proteins that are significant contributors to, and thus indicators of, cardiac disease. More...
By leveraging microelectronics components and microfabrication techniques developed initially for the electronic industry, they developed a series of compact nano-biochip sensor devices that are biochemically-programmed to detect sets of these proteins in saliva.

The researchers then tested saliva from 56 people who had a heart attack and 59 healthy subjects for 32 proteins associated with atherosclerosis, thrombosis, and acute coronary syndrome (ACS). They found these proteins were in higher concentrations in saliva of heart attack victims, and that specific salivary proteins were as accurate in the diagnosis of heart attack as of those found in blood serum using current testing methods. The test involves saliva transferred to a credit card-sized lab card that holds the nano-biochip. The loaded card is then inserted into an analyzer that manipulates the sample and analyses the patient's cardiac status on the spot. The new sensor was presented at the annual of the American Association for Dental Research (AADR), held during April 2008 in Dallas (TX, USA).

"Many heart attack victims, especially women, experience nonspecific symptoms and secure medical help too late after permanent damage to the cardiac tissue has occurred,” said principal investigator and designer of the nano-biochip, John McDevitt, Ph.D., a professor of chemistry and biochemistry at UT. "What's novel here is our ability to measure all such proteins in one setting and to use a noninvasive saliva sample, where low protein levels make such tests difficult even with large and expensive lab instruments.”


Related Links:
University of Texas
University of Kentucky
University of Louisville

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
POC Immunoassay Analyzer
Procise DX
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.